Vertex Pharmaceuticals Incorporated 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-06-05 4:10 pm Sale | 2023-06-01 | 13D | Kymera Therapeutics, Inc. KYMR | VERTEX PHARMACEUTICALS INC VRTX | 0 0.000% | -3,151,121 (Position Closed) | Filing |
| 2020-09-03 4:12 pm Purchase | 2020-08-25 | 13D | Kymera Therapeutics, Inc. KYMR | VERTEX PHARMACEUTICALS INC VRTX | 3,151,121 7.100% | 3,151,121 (New Position) | Filing |